Considering Interim Interventions to Control COVID-19 Associated Morbidity and Mortality – The Perspectives

Abstract

As coronavirus (COVID-19) disease is evolving rapidly, there is a growing need to discuss the elements of coordinated strategy to control the spread and mitigate the severity and mortality of COVID-19. Apart from confinement and sanitation measures, which are temporary, we need consider using existing and readily available medications for use. H1N1 vaccine and streptococcus pneumoniae vaccines are traditionally available. The current report discusses the possible methods for reduction in coronavirus related morbidity and mortality using these vaccine measures effectively as an inexpensive primary care strategy; before a dedicated vaccine for coronaviruses emerges for regular clinical use. A significant reduction in the need for intensive care unit admissions, ventilators, and thereby reducing mortality, would translate into considerable benefits in health care dynamics and the global economy.

Keywords: Coronavirus, COVID-19, influenza vaccine, pneumococcal vaccine, pathogenesis

JEL Classification: I, E